Can fish oil supplementation lead to cognitive enhancement in Type 2 Diabetes?

Not Applicable

• Conditions: Type 2 Diabetes Mellitus; Cognitive decline; Metabolic and Endocrine - Diabetes; Neurological - Other neurological disorders; Diet and Nutrition - Other diet and nutrition disorders

• Registration Number: ACTRN12616000153415
• Lead Sponsor: a Trobe Univeristy

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-02-09
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 78

Inclusion Criteria

Diagnosed Type 2 diabetes ( diet controlled, taking oral hypoglycaemic agents or insulin)
Greater or equal to 50 years of ages
Not taking omega 3 supplements
Low habitual consumption of oily fish ( < 100g 3 times per week)
Fluent in English

Exclusion Criteria

Less than 50 years of age
Clinically established history of psychiatric disorder including depression and substance/ alcohol abuse
Clinically established history of co-morbid neurological disorder liable to affect cognition, including dementia
Taking omega 3 supplements
High habitual consumption of oily fish ( > 100g 3 times per week)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in cognitive test scores ( Standardised Mini Mental State Examination ( SMMSE), California Verbal Learning Test- second edition ( CVLT-II), computerised test of information processing, (CTIP) )[From baseline, 3 months and 6 months after commencement of intervention.];Change in Inflammatory cytokines ( Il-6, IL-1b, TNF-a, CRP) as measured in blood sample[From baseline, 3 months and 6 months after commencement of intervention.];Change in Oxidative stress ( F2 Isoprostane) as measured in blood sample[From baseline, 3 months and 6 months after commencement of intervention.]

Secondary Outcome Measures

Name	Time	Method
change in erythrocyte DHA levels[From baseline, 3 months and 6 months after commencement of intervention.];Change in Hba1C as measured in blood sample [From baseline, 3 months and 6 months after commencement of intervention.];Change in blood lipids as measured in blood sample[From baseline, 3 months and 6 months after commencement of intervention.]